PM Modi congratulates nation after emergency use approval to COVID-19 vaccines

TOP NEWS
Typography

COVID-19 vaccines of Serum Institue of India and Bharat Biotech have been granted permission for restricted use in emergency situation

 

Prime Minister Narendra Modi congratulated the country as Drugs Controller General of India (DCGI) granted emergency use approval to Serum Institute of India and Bharat Biotech for their COVID-19 vaccines on Sunday.

In a series of tweet, the Prime Minister expressed gratitude to the frontline workers who are involved in the fight against the COVID-19.

"A decisive turning point to strengthen a spirited fight! DCGI granting approval to vaccines of @SerumInstIndia and @BharatBiotech accelerates the road to a healthier and COVID-free nation. Congratulations India. Congratulations to our hardworking scientists and innovators," Modi tweeted.

PM said it would make every Indian proud that the two Covid-19 vaccines that have been given approval by the DCGI are 'made in India'.

"It would make every Indian proud that the two vaccines that have been given emergency use approval are made in India! This shows the eagerness of our scientific community to fulfil the dream of an Aatmanirbhar Bharat, at the root of which is care and compassion," he added.

The Prime Minister also thanked frontline coronavirus warriors and expressed gratitude towards them.

"We reiterate our gratitude to doctors, medical staff, scientists, police personnel, sanitation workers and all Corona warriors for the outstanding work done, that too in adverse circumstances. We will remain eternally grateful to them for saving many lives," another tweet said.

The Prime Minister’s tweet came after Drugs Controller General of India VG Somani announced the approval for the emergency-use of two coronavirus vaccines, one developed by AstraZeneca and Oxford University and the other by Bharat Biotech

"After adequate examination, CDSCO has decided to accept the recommendations of the Expert Committee and accordingly, vaccines of M/s Serum and M/s Bharat Biotech are being approved for restricted use in emergency situation and permission is being granted to M/s Cadila Healthcare for conduct of the Phase III clinical trial," said VG Somani. 

 

With inputs from Agency

Image credit: Business Today

All Comments